Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2018, Article ID 5821369, 6 pages
Research Article

Effects of Propranolol on Neurodevelopmental Outcomes in Patients with Infantile Hemangioma: A Case-Control Study

1Division of Oncology, Department of Pediatric Surgery, West China Hospital of Sichuan University, Chengdu 610041, China
2Pediatric Intensive Care Unit, Department of Critical Care Medicine, West China Hospital of Sichuan University, Chengdu 610041, China
3Department of Child Health, West China Second University Hospital, Sichuan University, Chengdu 610041, China

Correspondence should be addressed to Yi Ji; moc.361@nauynauyijij

Received 9 September 2017; Revised 28 December 2017; Accepted 4 January 2018; Published 25 February 2018

Academic Editor: Jean Kanitakis

Copyright © 2018 Chuan Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Background. The aim of this study was to examine whether oral propranolol has any effect on neurodevelopment outcomes in young children with problematic infantile hemangiomas (IHs). Methods. Thirty-six children with a diagnosis of problematic IH who were treated with oral propranolol were compared with 34 healthy children with no history of propranolol therapy. Patients received propranolol therapy for at least 3 months. Gesell developmental schedules (GDS) were used to evaluate neurodevelopment outcomes in the two groups. The scores of each GDS domain were compared between the two groups. Results. There were no significant differences in developmental quotient (DQ) values for any of the five domains between the patients and healthy controls . Multiple stepwise regression analyses showed that none of the domains in the control group were influenced by the children’s gender or age . In addition, we found that gender, age at the initiation of therapy, age at the time of the neurodevelopment test, and treatment duration had no effect on any domain of the GDS in the patient group . Conclusion. Propranolol has no obvious effect on neurodevelopmental outcomes in children. Early treatment and treatment duration had no negative effect on central nervous system (CNS) development.